Neogen (Neogen) Debt-to-Equity

: 0.28 (As of Feb. 2024)

View and export this data going back to 1989. Start your Free Trial

Neogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $2.5 Mil. Neogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $887.7 Mil. Neogen's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $3,146.2 Mil. Neogen's debt to equity for the quarter that ended in Feb. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neogen's Debt-to-Equity or its related term are showing as below:

NEOG' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28 Med: 0.28 Max: 0.3
Current: 0.28

During the past 13 years, the highest Debt-to-Equity Ratio of Neogen was 0.30. The lowest was 0.28. And the median was 0.28.

NEOG's Debt-to-Equity is ranked worse than
53.3% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs NEOG: 0.28

Neogen Debt-to-Equity Historical Data

The historical data trend for Neogen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Debt-to-Equity

Get a 7-Day Free Trial

0.28

Neogen Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															0.28	0.28	0.28	0.28	0.28

Competitive Comparison

For the Diagnostics & Research subindustry, Neogen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neogen Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neogen's Debt-to-Equity falls into.

Neogen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neogen's Debt to Equity Ratio for the fiscal year that ended in May. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	885.439)	/	3134.217
	=	0.28

Neogen's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.521	+	887.653)	/	3146.174
	=	0.28

Neogen (NAS:NEOG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neogen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neogen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neogen (Neogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (NAS:NEOG) » Definitions » Debt-to-Equity

Comparable Companies

SHC RDNT GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

NG2:Germany NG2:Germany

Address

620 Lesher Place, Lansing, MI, USA, 48912

Website

https://www.neogen.com

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Executives

William T Boehm	director
Douglas Edward Jones	officer: Vice President, CCO	620 LESHER PLACE, LANSING MI 48912
Jason Warren Lilly	officer: Vice President	620 LESHER PLACE, LANSING MI 48912
James P Tobin	director	620 LESHER PLACE, LANSING MI 48895
David H. Naemura	officer: VP & CFO	C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Amy M Rocklin	officer: Chief Legal & Reg. Officer	620 LESHER PLACE, LANSING MI 48912
Steven J. Quinlan	officer: VP & CFO	620 LESHER PLACE, LANSING MI 48912
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Aashima Gupta	director	C/O NEOGEN CORPORATION, 620 LESHER PLACE, LANSING MI 48912
John Edward Adent	officer: Chief Executive Officer	822 7TH STREET, SUITE 740, GREELEY CO 80631
Darci L Vetter	director	620 LESHER PLACE, LANSING MI 48912
Ronald D Green	director	620 LESHER PLACE, LANSING MI 48912
James C Borel	director	1007 MARKET STREET, WILMINGTON DE 19898
Terri A Morrical	officer: General Manager
G Bruce Papesh	director	726 APPLEGATE LANE, EAST LANSING MI 48823